Deutsch · English
Research & Regulatory
A factual overview — no usage or dosage guidance
Note upfront: This article summarizes the regulatory status of research peptides. It is information only, not medical advice and not a usage or dosage recommendation. All substances offered by PeptiX are intended exclusively for laboratory and research purposes (Research Use Only) and are not approved for human or animal use.
FDA update 2026: twelve peptides removed from "Category 2"
The U.S. FDA maintains what is known as the 503A Bulk Drug Substances List. It governs which active substances U.S. compounding pharmacies may individually prepare on a physician's prescription. In 2023 the FDA had placed 19 peptides into the restrictive "Category 2" (significant safety concerns), which stopped compounding.
On 15 April 2026 the FDA removed twelve of these peptides from Category 2. Important for context: this is not an approval. The substances still cannot be routinely compounded and are not FDA-approved — they are simply no longer expressly prohibited. Final inclusion in the regular list is a separate process that is only just beginning.
Next step: PCAC hearing in July 2026
An independent FDA advisory panel — the Pharmacy Compounding Advisory Committee (PCAC) — reviews seven of these peptides on 23 and 24 July 2026 for possible inclusion in the regular list. A realistic, legal compounding pathway in the U.S. would — if things proceed favorably — be expected no earlier than 2027, and even then only in the United States.
Affected substances
Removed from Category 2 were: BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon, LL-37, GHK-Cu (injectable), PEG-MGF, Melanotan II and DiHexa. You can find the factual research context for individual substances in our peptide lexicon.
What does this mean by region?
United States: the status has shifted within the compounding framework, but the substances remain non-approved. Germany/EU: nothing changes in regulatory terms — the peptides remain non-approved, experimental substances or research chemicals, available exclusively for laboratory and research purposes and not for use in humans. Worldwide: the legal framework differs by country; purchase, possession and use are the buyer's own responsibility to verify.
For context: not every substance is the same
The regulatory status differs — sometimes substantially — from substance to substance. Active compounds that are approaching a regular approval process and are under patent protection — such as certain incretin analogues — fall under a different, stricter framework; distribution outside authorized channels can be legally challengeable there. We monitor these developments and align our offering exclusively with the Research-Use-Only framework.
Questions about the regulatory context? [email protected]
As of July 2026. Sources: FDA — Pharmacy Compounding Advisory Committee (meeting 23–24 July 2026) and 503A Bulk Drug Substances; public docket FDA-2025-N-6895.